Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece
Open Access
- 21 November 2022
- journal article
- research article
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 14 (4), 9265
- https://doi.org/10.4081/dr.2022.9265
Abstract
Etanercept is approved for continuous or intermittent use and flexible dosing in plaque psoriasis (PsO). The objectives of this study were to investigate real-world treatment patterns with etanercept in Greek adults with moderate-to-severe PsO. This non-interventional multicenter study included a retrospectiveto- prospective (RP) cohort, previously treated with etanercept for ≥24 months and followed for an additional 6 months, and a biologic-naïve, prospective-only (PO) cohort, followed for 6 months after treatment initiation. Parameters assessed included Psoriasis Area and Severity Index (PASI), percentage of body surface area (BSA) affected, Dermatology Life Quality Index (DLQI), and adverse events (AEs). This study enrolled 123 patients (RP, n = 56; PO, n = 67), who mostly adhered to continuous treatment (RP, 68%; PO, 95%). The two cohorts had similar mean baseline-to-endpoint decreases in PASI (-9.5 vs -10.1) and BSA (-11.9 vs -12.3). The PO-CTP population had a mean DLQI baseline-to-endpoint score decrease of -5.8, which was statistically significant and clinically meaningful. Treatment-emergent AE rates were 58.9% (RP) versus 26.9% (PO). These real-world data suggest a similar effectiveness of continuous and intermittent etanercept treatment in Greek patients with PsO.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-UpDermatology, 2012
- Intermittent etanercept therapy in pediatric patients with psoriasisJournal of the American Academy of Dermatology, 2010
- Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanerceptBritish Journal of Dermatology, 2009
- Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasisJournal of the European Academy of Dermatology and Venereology, 2009
- Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL studyJournal of the European Academy of Dermatology and Venereology, 2009
- Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL studyExpert Review of Dermatology, 2008
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2008
- Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted TreatmentValue in Health, 2008
- A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 2007
- Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyJournal of Dermatological Treatment, 2006